Study: TripleHormone Receptor Agonist Retatrutide for Obesity (Phase 2 Trial, NEJM) Drug: Retatrutide a triple agonist (GLP-1, GIP, and glucagon receptors) Key Findings: Up to 28.7% mean weight loss at higher doses Marked improvements in insulin sensitivity and cardiometabolic risk factors Weight loss approaching outcomes seen with bariatric surgery, without surgery What makes Retatrutide unique is its triple-hormone mechanism, simultaneously targeting appetite regulation, energy expenditure, and glucose metabolism

This test is recommended when you are looking for information about: Sex hormones (estrogens, progesterone, testosterone) production and metabolic patterns Adrenal hormones (DHEA and cortisol) production and metabolic patterns Diurnal free cortisol and cortisone patterns Melatonin production through the night Micronutrient availability and oxidative stress (targeted organic acids panel) Finding the Right Test Selecting the right test is essential for achieving health goals and providing the necessary level of detail
Sensitivity analysis based on T2DM The effects of GLP-1RA in the T2DM population were largely congruent with the overall population, except for its effects on the rates of coronary revascularization
Ozempic Dosage for Weight Loss The Ozempic dosage for weight loss is typically titrated up to a maximum dose of 2mg weekly, as tolerated by each individual patient